Arimidex: Advanced Estrogen Control for Breast Cancer Treatment
| Product dosage: 1mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $5.56 | $166.84 (0%) | 🛒 Add to cart |
| 60 | $4.54 | $333.68 $272.62 (18%) | 🛒 Add to cart |
| 90 | $4.21
Best per pill | $500.52 $379.26 (24%) | 🛒 Add to cart |
Synonyms | |||
Arimidex (anastrozole) represents a significant advancement in hormonal therapy for hormone receptor-positive breast cancer in postmenopausal women. As a third-generation aromatase inhibitor, it works by selectively lowering estrogen levels throughout the body, creating an unfavorable environment for cancer cell growth and proliferation. This targeted mechanism offers a sophisticated approach to adjuvant treatment and metastatic disease management, with demonstrated efficacy in reducing recurrence risk and improving survival outcomes. Clinical evidence supports its position as a cornerstone therapy in modern oncology practice.
Features
- Contains 1 mg anastrozole per tablet
- Non-steroidal aromatase inhibitor class
- Oral administration once daily
- Bioavailability approximately 80% when taken without food
- Plasma protein binding: 40%
- Elimination half-life: approximately 50 hours
- Metabolized primarily by hepatic N-dealkylation, hydroxylation, and glucuronidation
- Excreted mainly via hepatic metabolism with renal excretion of metabolites
Benefits
- Significantly reduces the risk of cancer recurrence in early breast cancer
- Demonstrates superior efficacy compared to tamoxifen in hormone receptor-positive patients
- Favorable side effect profile with reduced risk of thromboembolic events compared to antiestrogens
- No associated risk of endometrial cancer unlike some alternative therapies
- Convenient once-daily dosing supports treatment adherence
- May improve disease-free survival in adjuvant treatment settings
Common use
Arimidex is primarily indicated for the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. It is also approved for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. Additionally, it is used for treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. The medication may be prescribed as extended adjuvant therapy following initial tamoxifen treatment in certain clinical scenarios.
Dosage and direction
The recommended dosage is one 1 mg tablet taken orally once daily, with or without food. For adjuvant treatment of early breast cancer, the duration typically continues for five years unless disease progression or unacceptable toxicity occurs. Patients should take the medication at approximately the same time each day to maintain consistent drug levels. Tablets should be swallowed whole with water and not crushed or chewed. Dosage adjustment is not typically required for elderly patients or those with mild-to-moderate hepatic impairment, though careful monitoring is advised.
Precautions
Regular monitoring of bone mineral density is recommended due to the increased risk of osteoporosis and fractures associated with estrogen suppression. Liver function tests should be performed periodically as elevations in serum transaminases have been observed. Patients should be monitored for signs and symptoms of carpal tunnel syndrome, which may occur with long-term use. Caution is advised in patients with pre-existing ischemic heart disease, as aromatase inhibitors may affect lipid metabolism. Vitamin D and calcium supplementation should be considered to support bone health during treatment.
Contraindications
Arimidex is contraindicated in women with known hypersensitivity to anastrozole or any components of the formulation. It must not be used in premenopausal women, pregnant women, or during lactation. The medication is contraindicated in patients with severe hepatic impairment (Child-Pugh class C). Concomitant use with estrogen-containing therapies is contraindicated as it may interfere with the pharmacological action of anastrozole. Patients with severe renal impairment (creatinine clearance <30 mL/min) should not use this medication without careful risk-benefit assessment.
Possible side effect
Common adverse reactions include hot flashes (35%), arthritis/arthralgia (30%), asthenia (19%), pain (17%), and headache (13%). Less frequent but clinically significant effects may include nausea (11%), depression (13%), hypertension (11%), and peripheral edema (10%). Serious side effects can include cardiovascular events, osteoporosis with increased fracture risk, and elevated cholesterol levels. Approximately 3% of patients may experience carpal tunnel syndrome with long-term use. Regular monitoring can help detect and manage these effects early.
Drug interaction
Tamoxifen co-administration reduces anastrozole plasma concentrations by 27% and should be avoided. Estrogen-containing therapies may diminish the pharmacological effect of anastrozole. CYP3A4 inducers such as rifampicin may decrease anastrozole concentrations, while strong CYP3A4 inhibitors might increase exposure. Caution is advised with medications that affect bone metabolism, including corticosteroids and certain anticonvulsants. The medication may interact with drugs that undergo extensive hepatic metabolism via cytochrome P450 enzymes.
Missed dose
If a dose is missed, patients should take it as soon as remembered unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should not double the dose to make up for a missed administration. Consistent daily dosing is important for maintaining therapeutic efficacy, so establishing a routine (such as using a pill organizer or daily reminder) is recommended to minimize missed doses.
Overdose
There is limited clinical experience with Arimidex overdose. Single doses up to 60 mg have been administered without serious adverse effects. In case of suspected overdose, symptomatic and supportive treatment is recommended. Gastric lavage may be considered if ingestion occurred recently. As anastrozole is not dialyzable due to high protein binding, hemodialysis is not expected to be beneficial. Medical attention should be sought immediately for appropriate monitoring and management of potential effects.
Storage
Store at room temperature between 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F). Keep the medication in its original container with the lid tightly closed to protect from moisture and light. Tablets should be kept out of reach of children and pets. Do not store in bathrooms or other areas with high humidity. Properly discard any medication that is outdated or no longer needed through medication take-back programs.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Treatment decisions should be made in consultation with a qualified healthcare professional who can consider individual patient factors, including complete medical history, current medications, and specific clinical circumstances. Dosage and treatment duration should be determined by a physician familiar with the patient’s condition. Always follow the prescribing information provided with the medication and report any adverse effects to your healthcare provider.
Reviews
Clinical studies demonstrate that Arimidex significantly improves disease-free survival compared to tamoxifen in hormone receptor-positive breast cancer patients. The ATAC trial showed a 24% reduction in recurrence risk with anastrozole versus tamoxifen. Many oncologists report favorable patient tolerance, though management of musculoskeletal symptoms requires attention. Long-term follow-up data confirms sustained efficacy with appropriate bone health management. Patient-reported outcomes indicate high satisfaction with treatment efficacy despite manageable side effects in most cases.